Core Viewpoint - The article emphasizes Bayer's long-term commitment to the Chinese market, highlighting its strategic investments and innovations that align with China's economic policies and development goals [1][2][3]. Group 1: Bayer's Historical Commitment to China - Bayer has been rooted in China for 144 years, marking its presence as one of the earliest multinational companies in the country [2]. - The establishment of Bayer China Limited in 1994 signified a systematic and comprehensive approach to its operations in China, evolving from trade to a full ecosystem of manufacturing, research, and innovation [2]. - Over the past three decades, Bayer has continuously increased its investment in China, including modern pharmaceutical production facilities and research centers [3]. Group 2: Recent Developments and Investments - In 2024, Bayer will launch two major research and innovation platforms in Shanghai, and by 2025, it will open a manufacturing center for crop protection products in Hangzhou with an investment exceeding 300 million RMB [3]. - As of March 2026, Bayer is expected to employ around 7,000 people in China and has established multiple supply and research centers [3]. Group 3: Alignment with Chinese Policies - Bayer's mission of "shared health and eliminating hunger" aligns with China's emphasis on biomedicine as a new pillar industry and its initiatives for rural revitalization and agricultural modernization [6][8]. - The company has successfully launched 19 innovative prescription drugs in China, reflecting its ability to synchronize with the country's drug approval processes [6]. Group 4: Innovation and Collaboration - Bayer is transitioning from merely introducing global innovations to enabling Chinese innovations to reach the world, exemplified by its partnerships with top Chinese universities and local biotech firms [11][12]. - The Bayer Co.Lab in China supports startups by providing funding, technical empowerment, and global networking opportunities, facilitating their entry into international markets [12]. Group 5: Future Outlook - Bayer aims to continue collaborating with Chinese innovation partners to build a community that benefits both China and the global market, contributing to sustainable development and national strategic goals [12].

Core Viewpoint - The company has received a notice of acceptance for the listing application of Finerenone raw materials from the National Medical Products Administration, indicating progress in the registration review phase for this new drug [1] Group 1: Product Development - Finerenone is a novel mineralocorticoid receptor antagonist intended for adult patients with type 2 diabetes-related chronic kidney disease [1] - As of the announcement date, five companies have registered the raw material with status "A," while the others are marked as "I" [1] Group 2: Market Impact - The acceptance of the application does not have a significant impact on the company's recent performance, but successful approval could enhance the company's raw material product pipeline [1] - The timeline and outcome of the registration approval remain uncertain, which may pose risks for investors [1]

Core Viewpoint - The research indicates that the antifibrotic drug Finerenone has the potential to restore fertility in women with Premature Ovarian Insufficiency (POI), a condition affecting approximately 1% to 3% of women under 40 years old, which is currently considered irreversible and lacks effective treatments [2][5]. Group 1: Research Findings - Finerenone, originally used for treating chronic kidney disease and heart failure related to type 2 diabetes, has shown promise in stimulating follicle development in aged mice and restoring follicular development in women with POI [3][6]. - The study revealed that Finerenone reduces collagen deposition in the ovarian stroma, alleviating the inhibitory effects of fibrosis on follicle development, thus creating a more favorable microenvironment for follicle activation and growth [6][9]. - A clinical trial involving 14 women diagnosed with POI demonstrated that all participants observed follicle development after treatment with Finerenone, leading to the production of viable embryos in some cases [6][7]. Group 2: Mechanism of Action - The mechanism of Finerenone involves blocking the overactivation of mineralocorticoid receptors, which leads to inflammation, fibrosis, and oxidative stress, thereby addressing the underlying issues in POI [5][6]. - The research team identified other FDA-approved oral antifibrotic drugs, such as Nintedanib and Ruxolitinib, which may also promote ovarian follicle growth, highlighting the clinical potential of repurposing these drugs for treating infertility related to POI [7][9]. Group 3: Implications for Treatment - The findings suggest a paradigm shift in the treatment strategy for POI, moving from directly stimulating follicles to improving the fibrotic condition of the ovarian stroma, which is identified as a key target for intervention [9]. - The study provides compelling evidence for the repurposing of Finerenone, emphasizing its safety and potential effectiveness in treating infertility associated with POI [5][9].

Core Viewpoint - The announcement highlights that Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Fenofibrate, to be used in marketed formulations, making it the second domestic company to achieve this approval [1] Group 1 - Fenofibrate is primarily used for adult patients with chronic kidney disease associated with type 2 diabetes [1] - The drug can reduce the risk of a sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, cardiovascular death, and hospitalization due to heart failure [1]

Core Viewpoint - The approval of non-naloxone by the National Medical Products Administration of China marks a significant milestone for the company, as it becomes the second domestic enterprise to receive such approval for this active pharmaceutical ingredient [1] Group 1: Company Developments - The company has received approval for non-naloxone to be used as an active pharmaceutical ingredient in marketed formulations [1] - Non-naloxone is primarily indicated for adult patients with chronic kidney disease associated with type 2 diabetes [1] Group 2: Product Significance - The drug is designed to reduce the risk of a sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular mortality, and hospitalization due to heart failure [1]

Core Viewpoint - The approval of non-naloxone by the National Medical Products Administration of China marks a significant milestone for the company, as it becomes the second domestic enterprise to receive such approval for this active pharmaceutical ingredient [1] Group 1: Company Developments - The company, Shijiazhuang Fourth Pharmaceutical Group, has announced that its non-naloxone has been approved for registration as an active pharmaceutical ingredient for use in marketed formulations [1] - This approval positions the company as a key player in the market for treatments related to chronic kidney disease associated with type 2 diabetes [1] Group 2: Product Significance - Non-naloxone is primarily used for adult patients with chronic kidney disease related to type 2 diabetes, and it is effective in reducing the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, cardiovascular mortality, and hospitalization due to heart failure [1]

Core Viewpoint - The approval of non-naloxone by the National Medical Products Administration of China marks a significant milestone for the company, establishing it as the second domestic enterprise to receive such approval for this active pharmaceutical ingredient [1] Group 1: Company Developments - The company has received approval for non-naloxone to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] - Non-naloxone is primarily used for adult patients with chronic kidney disease associated with type 2 diabetes, helping to reduce the risk of decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization due to heart failure [1] Group 2: Industry Context - The approval positions the company as a key player in the domestic pharmaceutical industry, particularly in the treatment of chronic kidney disease related to diabetes [1] - This development reflects the growing focus on chronic diseases in the healthcare sector, highlighting the importance of innovative treatments in managing such conditions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的非奈利酮已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥，是國 內企業第二家獲批。 非奈利酮主要用於與2型糖尿病相關的慢性腎臟病成人患者，可降低腎小球濾過率估計值(eGFR) 持續下降、終末期腎病、心血管死亡及因心力衰竭住院的風險。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十二月五日 ...